» Authors » Bitna Kim

Bitna Kim

Explore the profile of Bitna Kim including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 104
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Shin E, Park Y, Lee J, Her A, Chon M, Kim S, et al.
JACC Asia . 2025 Jan; 5(1):15-24. PMID: 39886190
Background: The Genoss paclitaxel-coated balloon (PCB) is a novel PCB with shellac and vitamin E as excipients, enhancing drug delivery to the target lesion and minimizing restenosis. Objectives: This study...
3.
Her A, Kim T, Shin E, Kim S, Kim B, Kim Y, et al.
Catheter Cardiovasc Interv . 2025 Jan; PMID: 39840648
Background: There is a paucity of data regarding drug-coated balloon (DCB) treatment in the context of left main (LM) true bifurcation lesions. Aims: The aim of this study was to...
4.
Kang D, Kim S, Kim B, Her A, Shin E
Sci Rep . 2024 Oct; 14(1):24260. PMID: 39414874
Drug-coated balloons (DCB) are increasingly utilized in percutaneous coronary intervention (PCI), but their effectiveness in coronary artery disease (CAD) needs further exploration. This study investigates the efficacy and safety of...
5.
Shin E, Her A, Jang M, Kim B, Kim S, Liew H
J Clin Med . 2024 Jun; 13(12). PMID: 38929910
Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) for chronic total coronary occlusions (CTOs) improves clinical symptoms and quality of life. However, data on drug-coated balloon (DCB)-based PCI in...
6.
Kim B, Royle M
J Child Psychol Psychiatry . 2024 May; PMID: 38772385
Adverse childhood experiences (ACEs) significantly impact lifelong health and well-being. Despite extensive research, a comprehensive understanding of ACEs' multifaceted impacts continues to be challenging to achieve. This study synthesizes meta-analytic...
7.
Her A, Kim B, Kim S, Kim Y, Scheller B, Shin E
Eur J Med Res . 2024 May; 29(1):280. PMID: 38735968
Objectives: Data on side-branch (SB) ostial effect after drug-coated balloon (DCB) treatment in the context of de novo coronary bifurcation lesions are limited. We aimed to investigate the angiographic outcomes...
8.
Shin E, Jun E, Kim B, Kim C, Park M, Choo E, et al.
Front Cardiovasc Med . 2024 Apr; 11:1358657. PMID: 38586173
Background: The TALOS-AMI study highlighted the effectiveness of a de-escalation strategy shifting from ticagrelor to clopidogrel 1 month after percutaneous coronary intervention (PCI), resulting in significant reduction in clinical events,...
9.
Shin E, Her A, Kim B, Hahn J, Song Y, Lee J, et al.
J Korean Med Sci . 2023 Nov; 38(45):e383. PMID: 37987108
Background: In patients undergoing percutaneous coronary intervention (PCI) in the SMART-CHOICE trial, P2Y12 inhibitor monotherapy after three months of dual antiplatelet therapy (DAPT) achieved clinical outcomes comparable to those of...
10.
Jun E, Hong S, Kim B, Lee J, Shin E
Catheter Cardiovasc Interv . 2023 Oct; 102(6):1040-1047. PMID: 37855180
Background: Genoss drug-eluting stent (DES) (Genoss Company Limited) is a new ultrathin sirolimus-eluting stent with an abluminal biodegradable polymer and a cobalt-chromium platform. Aims: The aim of this study was...